Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.8.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Income Statement [Abstract]    
Research and development revenue $ 231 $ 1,760
Grant revenue 251 125
Total revenue 482 1,885
Operating expenses:    
Research and development 6,687 1,067
General and administrative 2,910 1,791
Total operating expenses 9,597 2,858
Loss from operations 9,115 973
Interest and other income, net 82 0
Interest expense (295) (223)
Change in fair value of warrant liabilities 614 1
Net loss 8,714 1,195
Deemed dividends on preferred stock 0 427
Net loss attributable to common shareholders $ 8,714 $ 1,622
Net loss per share attributable to common shareholders:    
Basic and diluted $ 0.32 $ 7.56
Weighted average number of shares used in net loss per share calculations:    
Basic and diluted 26,989,693 214,641
Other comprehensive loss:    
Unrealized gain (loss) on available-for-sale securities $ 0 $ 0
Comprehensive loss $ 8,714 $ 1,622